Cargando…
Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HI...
Autores principales: | Benzaquen, Ella, Wang, Yifan, Wiseman, Stephanie, Rosenfeld, Velka, Sideris, Lucas, Dubé, Pierre, Pelletier, Jean-Sebastien, Vanounou, Tsafrir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Joule Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064255/ https://www.ncbi.nlm.nih.gov/pubmed/33651573 http://dx.doi.org/10.1503/cjs.001619 |
Ejemplares similares
-
Case series on high grade appendiceal cancer with peritoneal and liver carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Roy, Susmit Prosun, et al.
Publicado: (2022) -
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations
por: Pelz, Joerg OW, et al.
Publicado: (2006) -
Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis
por: Marcotte, Eric, et al.
Publicado: (2014) -
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
por: Vassos, Nikolaos, et al.
Publicado: (2016) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
por: Roh, Seung Jae, et al.
Publicado: (2020)